Four compound names leave four different questions.
A blood test and a heart attack don’t belong on the same scoreboard. I check what each study measured before comparing these four names. Semaglutide, tesamorelin, ipamorelin and NAD+ attract overlapping hopes, but their evidence answers different questions. NAD+ isn’t even a peptide: it’s a helper molecule used in cellular reactions.
Compare the result you care about, not just the names attached to it.
What was actually measured?
This table is a reading map. The linked pages explain the findings and their cautions. “Muscle” can mean size, strength or how tissue handles sugar; seeing that word doesn’t tell you which was tested.
I also keep the ingredient visible. Research on a precursor, an ingredient the body uses to make NAD+, isn’t automatically research on an NAD+ injection. A shorter label can hide quite a large difference.
You can use the last column to spot those gaps. If it doesn’t name the outcome you’re interested in, that question still needs an answer.
| Interest | Read about | What the studies measured |
|---|---|---|
| Appetite | Semaglutide | Body weight; heart events in a separate trial. |
| Visceral fat | Tesamorelin | Deep abdominal fat in adults with HIV-associated fat changes. |
| Muscle | Ipamorelin | Growth-hormone release; eating after bowel surgery. |
| Energy | NAD+ | Blood NAD+ with oral precursors; muscle response to insulin with NMN. |
The people in the study matter
The semaglutide heart trial studied adults aged 45 or older who already had heart or blood-vessel disease, with overweight or obesity and without diabetes. The tesamorelin fat trial studied adults with HIV and abdominal fat accumulation. Those descriptions limit how far either result can travel.
The NMN trial found that muscle responded better to insulin, the hormone that helps tissues handle blood sugar, in women after menopause with prediabetes. Their body composition didn’t change. Better insulin response didn’t mean bigger muscles.
Ipamorelin’s volunteer study measured growth-hormone release. It didn’t show that someone hoping for more muscle got stronger.
Time and side effects can change the picture
Tesamorelin’s follow-up research found that visceral fat returned after treatment stopped. A benefit during treatment and a lasting benefit afterward are different things to weigh.
For semaglutide, the digestive side effects belong beside the weight result. For ipamorelin, FDA reports serious events, including deaths, in the intravenous bowel-surgery trial, with ipamorelin’s part unclear. Missing safety evidence isn’t reassuring evidence.
If you arrived wanting a single winner, I understand the appeal. But “best” needs a condition, a person and an outcome. This page helps sort the words; a clinician has to assess whether a treatment fits the person.